PO.IM02.07 · 免疫学

晚期卵巢癌建模及验证用于转基因表达和肿瘤监测的溶瘤腺病毒工具

Modeling late-stage ovarian cancer and validating oncolytic adenoviral tools for transgene expression and tumor monitoring

海报缩略图:晚期卵巢癌建模及验证用于转基因表达和肿瘤监测的溶瘤腺病毒工具
编号 6984 展板 12 时间 4/22 09:00–12:00 区域 Section 8 主讲 Lakshmi Kadkol, BS
分会场 Novel Models of Immunotherapy Response
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Lakshmi Kadkol1, Eric Gauchat2, Maria Jose Godoy Calderon1, Manali Patwardhan1, VK Gadi1

1Medicine, University of Illinois at Chicago, Chicago, IL,2Cancer Center, University of Illinois at Chicago, Chicago, IL

摘要 Abstract

中文摘要
目的:高级别浆液性卵巢癌(HGSOC)以显著的免疫排斥和腹膜播散为特征,据推测由TGF-beta和GM-CSF细胞因子所协调。我们建立了一种免疫功能健全的晚期HGSOC小鼠模型,并评估了编码GM-CSF和/或可溶性TGF-beta受体Fc融合蛋白(sTGFbetaR-Fc)的hTERT驱动型溶瘤腺病毒的肿瘤选择性和转基因递送效率。 实验步骤:通过向免疫功能健全的FVB/N小鼠腹腔注射荧光素酶标记的MOE-KRAS/PTEN(MKP)细胞,建立了晚期HGSOC的同基因原位模型。通过生物发光成像(BLI)纵向监测肿瘤负荷。在体外评估了四种hTERT驱动型溶瘤腺病毒(Ad.Null、Ad.GM-CSF [Ad.GM]、Ad.sTGFbetaR [Ad.sT]、Ad.sTGFbetaR.GM-CSF [Ad.sT.GM])在MKP肿瘤细胞、NIH 3T3成纤维细胞以及3T3来源的癌相关成纤维细胞(CAF)中的感染性、细胞溶解活性(Incucyte/caspase 3/7)和转基因表达(流式细胞术)。 结果:连续BLI显示到第26天(n = 14)出现一致的腹膜肿瘤植入和进展,确认了该模型对晚期疾病的保真度。在体外,IncuCyte活细胞成像显示溶瘤感染后MKP细胞出现强烈、选择性的凋亡,而NIH 3T3成纤维细胞和CAF(非肿瘤对照)反应极小。MKP细胞的凋亡活性在感染后30-35小时急剧上升,并在45小时达到峰值(caspase3/7+面积较未处理组增加>60-80倍),而3T3和CAF中凋亡活性极小(较未处理组<8倍)。值得注意的是,在各病毒构建体中,Ad.GM和Ad.Null诱导了最快速、最强烈的凋亡,而Ad.sT和Ad.sT.GM则表现出显著延迟和减弱的效应(Ad.GM对比Ad.Null:p = 0.0042;Ad.sT对比Ad.GM或Ad.Null:p < 0.0001;双因素方差分析结合Sidak检验)。感染48小时后通过流式细胞术定量转基因表达。Ad.GM和Ad.sT.GM处理产生了GM-CSF阳性细胞(分别为2.25%和1.04%门控,平均荧光强度分别为6217.54和5508.2),而Ad.sT和Ad.sT.GM处理产生了sTGFbetaR-Fc阳性细胞(分别为8.04%和9.75%门控,平均荧光强度分别为85092.63和84097.65);与未处理(96.32%)对照相比,处理组的活细胞频率下降(61.45-67.83%)。这些结果表明,经工程改造的溶瘤构建体在肿瘤细胞中实现了选择性转基因表达和细胞毒性。 结论:这些数据确认了晚期HGSOC模型的保真度,并确立了溶瘤腺病毒平台作为有效的机制研究工具——既作为细胞溶解剂,又作为功能性转基因的递送载体——用于从机制上剖析卵巢癌中的TGF-beta和GM-CSF信号。
查看英文原文 English abstract
Purpose : High-grade serous ovarian cancer (HGSOC) is characterized by profound immune exclusion and peritoneal spread, hypothesized to be orchestrated by the TGF-beta and GM-CSF cytokines. We established an immunocompetent murine model of advanced HGSOC and evaluated the tumor selectivity and transgene delivery efficiency of hTERT-driven oncolytic adenoviruses encoding GM-CSF and/or a soluble TGF-beta receptor Fc fusion (sTGFbetaR-Fc). Experimental Procedures : A syngeneic orthotopic model of advanced HGSOC was established by intraperitoneally injecting luciferase-labeled MOE-KRAS/PTEN (MKP) cells into immunocompetent FVB/N mice. Tumor burden was monitored longitudinally by bioluminescence imaging (BLI). Four hTERT-driven oncolytic adenoviruses (Ad.Null, Ad.GM-CSF [Ad.GM], Ad.sTGFbetaR [Ad.sT], Ad.sTGFbetaR.GM-CSF [Ad.sT.GM]) were evaluated in vitro for infectivity, cytolytic activity (Incucyte/caspase 3/7), and transgene expression (flow cytometry) in MKP tumor cells, NIH 3T3 fibroblasts, and 3T3-derived cancer-associated fibroblasts (CAFs). Results : Serial BLI showed consistent peritoneal tumor engraftment and progression by day 26 (n = 14) confirming model fidelity for late-stage disease. In vitro, IncuCyte live-cell imaging revealed strong, selective apoptosis in MKP cells following oncolytic infection, while NIH 3T3 fibroblasts and CAFs (non-tumor controls) showed minimal response. Apoptotic activity in MKP cells rose sharply at 30-35 hours and peaked at 45 hours post-infection (>60-80% fold increase in caspase3/7+ area over untreated but minimal apoptotic activity in 3T3 and CAFs (<8-fold over untreated). Notably, among virus constructs, Ad.GM and Ad. Null induced the most rapid and robust apoptosis, whereas Ad. sT and Ad.sT.GM showed significantly delayed and reduced effects (Ad.GM vs Ad. Null: p = 0.0042; Ad. sT vs Ad.GM or Ad. Null: p < 0.0001; 2-way ANOVA with Sidak's test). Transgene expression was quantified by flow cytometry following 48-hour infection. Ad.GM and Ad.sT.GM treatments produced GM-CSF positive cells (2.25% and 1.04% gated, mean fluorescence intensity 6217.54 and 5508.2 respectively) while Ad.sT and Ad.sT.GM treatments produced sTGFbetaR-Fc positive cells (8.04% and 9.75% gated, mean fluorescence intensity 85092.63 and 84097.65 respectively); live cell frequencies decreased in treated groups (61.45-67.83%) compared to untreated (96.32%) controls. These results demonstrate selective transgene expression and cytotoxicity in tumor cells achieved by the engineered oncolytic constructs. Conclusions : These data confirm the fidelity for advanced-stage HGSOC model and establish oncolytic adenoviral platforms as effective mechanistic tools-functioning both as cytolytic agents and as delivery vehicles for functional transgenes-to mechanistically dissect TGF-beta and GM-CSF signaling in ovarian cancer.
利益披露 Disclosure
L. Kadkol, None.. E. Gauchat, None.. M. Godoy Calderon, None.. M. Patwardhan, None.. V. Gadi, None.

← 返回 AACR 2026 检索